Cancer Therapies (Clinical Trials)

Clearance Received To Initiate Head/Neck Cancer Trials in Canada

Published in Cancer Weekly, February 2nd, 1998

Genetronics Biomedical Ltd., Toronto, Ontario, Canada, announced it has received Canadian Health Protection Board clearance to initiate multi-center Phase II clinical trials in Canada utilizing its proprietary electroporation therapy to treat patients with squamous cell carcinoma of the head and neck who have failed conventional therapies.

Electroporation therapy uses electric fields generated by the Genetronics proprietary MedPulser to open momentary pores in human cells that allow more efficient entrance of an anti-tumor drug previously injected into the tumor. Genetronics believes preliminary data shows that very low dosages of the drug, Bleomycin, can be effective...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1998-02-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry